Corporate Symposia
*Lunch boxes will be provided to the session attendees (marked with* below)
Corporate Symposium (CS01) | Servier*
New Developments in Glioma Care: A Focus on Mutant IDH Inhibition
Click on the 
link to register.
Friday, September 22, 13:15 - 14:15 hrs, Grote Zaal
| 13:15 – 13:20 | Welcome & Introduction Meeting objectives; speaker introduction; agenda; housekeeping |
Carmen Balaña , Spain Unmet needs in current glioma management Riccardo Soffietti, Italy | |
| 13:20 – 13:35 | From Concept to Clinic – understanding the Journey to INDIGO. Rapid overview of the development of IDH mutation inhibitors for glioma. |
Tim Cloughesy, United States | |
| 13:35 – 13:50 | Interpreting pivotal clinical data in IDH Mutated Glioma in light of prior research and current practice. A deep dive into the results of the INDIGO trial in the context of previous studies and current clinical management |
Martin van den Bent, Netherlands | |
| 13:50 – 14:00 | Beyond the numbers: Contextualizing evidence through a patient case study Review of a patient case to illustrate the experience with IDH mutation inhibitors |
| Mehdi Touat, France | |
Envisioning the future of glioma management with molecular targeted therapy How will IDH mutation inhibitors change the future of the clinical management of glioma? Which patient population are likely to benefit from the treatment? | |
Matthias Preusser, Austria | |
| 13:30 – 13:45 | Q&A and Panel Discussion |
| All Faculty members, moderated by: Carmen Balaña , Spain |
Corporate Symposium (CS02) | SERB Pharmaceuticals*
IMPROVING PATIENT CARE: NEW PERSPECTIVES ON HDMTX TREATMENT IN NEURO-ONCOLOGY (click on the title to download a PDF programme)*
Friday, September 22, 13:15 - 14:15 hrs, Van Weelde Zaal
| 13:15 – 13:30 | HDTMX: a Cornerstone in Neuro-Oncology |
Scott Howard, United States | |
| 13:30 – 13:45 | Maximising Patient Care: Examples from the EU Registry |
Madhumita Dandapani, United Kingdom | |
| 13:45 – 14:00 | Strategies to Improve HDMTX Outcomes: Updates from the METHOGLU Study |
| Caroline Houillier, France | |
| 14:00 – 14:15 | Summary, Practical Advice, and Audience Questions |
All speakers |
Corporate Symposium (CS03) | Chimerix
H3 K27M-mutant Diffuse Glioma: Diagnosis to Treatment and Future Directions
Saturday, September 23, 13:00 - 14:00 hrs, Grote Zaal
| 13:00 – 13:05 | Welcome/Opening |
Allen Melemed, United States | |
| 13:05 – 13:20 | Epidemiology and Diagnosis of H3 K27M Diffuse Glioma |
Pieter Wesseling, Netherlands | |
| 13:20 – 13:35 | Treatment Landscape |
Susan Short, United Kingdom | |
| 13:35 – 13:50 | ACTION: Phase 3 Trial of ONC201 in H3 K27M-mutant Diffuse Glioma |
Martin van den Bent, Netherlands | |
| 13:50 – 14:00 | Panel Discussion and Q&A |
Panelists |
Corporate Symposium (CS04) | Novocure*
Tumor Treating Fields: In Application
Saturday, September 23, 13:00- 14:00 hrs, Willem Burger Zaal
Chairs: Martin Glas, Roberta Rudà
| 13:00 – 13:05 | Welcome/Opening |
Martin Glas, Germany | |
| 13:05 – 13:15 | TTFields therapy concomitant with TMZ and Lomustine |
Martin Glas, Germany | |
| 13:15 – 13:25 | Real-world experience with TTFields in GBM |
Martin Misch, Germany | |
| 13:25 – 13:35 | Investigating TTFields with ICI in GBM |
| Michael Weller, Switzerland | |
| 13:35 – 13:55 | Q&A Session |
| Elizabeth Moyal, France; Martin Glas, Germany | |
